Lexicon Pharmaceuticals Reports 3rd Quarter Financial Results And Discusses Collaboration With Sanofi For Sotagliflozin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Lexicon Pharma (LXRX) Tops Q3 EPS by 2c
November 6, 2015 9:15 AM ESTLexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.34), $0.02 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $566 thousand versus the consensus estimate of $370 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
... MoreSanofi (SNY), Lexicon Pharma (LXRX) Enter Sotagliflozin Commercialization, Development Agreement
November 6, 2015 6:26 AM ESTSanofi (NYSE: SNY) and Lexicon Pharma (Nasdaq: LXRX) announced that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
"This agreement with Lexicon reinforces our commitment to helping people living with diabetes," said Pascale Witz, Executive Vice President, Sanofi, who will lead the Global Diabetes and Cardiovascular Care Business Unit in the company's new organizational structure. "Adding... More
